EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Preimplantation Genetic Testing for Polygenetic Conditions: A Legal, Ethical, and Scientific Challenge

Perrine Ginod, Michael H Dahan

Seminars in Reproductive Medicine · 01.03.2024 · 42 (01) · 060-068

DOI: 10.1055/s-0044-1782618 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Seminars in Reproductive Medicine, erschienen am 01.03.2024. Verfasst von Perrine Ginod und 1 weiteren Autor:innen. Beteiligte Einrichtung: MUHC Reproductive Centre, McGill University, Montréal, Quebec, Canada. Hauptthemen laut MEDLINE: Preimplantation Diagnosis, Genetic Testing. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 64 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The recent commercialization of the Embryo Health Score (EHS), determined through preimplantation genetic testing for polygenic conditions, offers the potential to select embryos with lower disease risk, thus potentially enhancing offspring longevity and health. Lately, Orchid Health company increased testing from less than 20 diseases to more than 900+ conditions for birth defects. However, the “geneticization” of phenotype estimates to a health state erases the environmental part, including the in vitro fertilization potential risks, questioning its scientific usefulness. EHS is utilized in countries with minimal regulatory oversight and will likely expand, while it remains illegal in other countries due to ethical and legal dilemmas it raises about reproductive autonomy, discrimination, impacts on family dynamics, and genetic diversity. The shift toward commercialized polygenic embryo screening (PES) redefines healthcare relationships, turning prospective parents into consumers and altering the physician's role. Moreover, PES could increase social inequalities, stigmatize those not born following PES, and encourage “desirable” phenotypic or behavioral traits selection, leading to ethical drift. Addressing these issues is essential before further implementation and requires a collaborative approach involving political, governmental, and public health, alongside geneticists, ethicists, and fertility specialists, focusing on the societal implications and acceptability of testing for polygenic traits for embryo selection.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Preimplantation DiagnosisGenetic TestingHumansFemalePregnancyMultifactorial InheritanceFertilization in Vitro

Autor:innen und Institutionen

  • MUHC Reproductive Centre, McGill University, Montréal, Quebec, Canada.
  • CHU Dijon Bourgogne, Service de Gynécologie-Obstétrique et Assistance Médicale à la Procréation, Dijon, France.
  • Division of Reproductive Endocrinology and Infertility, Department of Obstetrics and Gynecology, McGill University, Montréal, Quebec, Canada.

Zitieren

APA

Ginod, P., & Dahan, M. H. (2024). Preimplantation Genetic Testing for Polygenetic Conditions: A Legal, Ethical, and Scientific Challenge. Seminars in Reproductive Medicine, 42(01), 060-068. https://doi.org/10.1055/s-0044-1782618

Vancouver

Ginod P, Dahan MH. Preimplantation Genetic Testing for Polygenetic Conditions: A Legal, Ethical, and Scientific Challenge. Seminars in Reproductive Medicine. 2024;42(01):060-068. doi:10.1055/s-0044-1782618

BibTeX
@article{Ginod2024,
  author = {Ginod, Perrine and Dahan, Michael H},
  title = {Preimplantation Genetic Testing for Polygenetic Conditions: A Legal, Ethical, and Scientific Challenge},
  journal = {Seminars in Reproductive Medicine},
  year = {2024},
  volume = {42},
  number = {01},
  pages = {060--068},
  doi = {10.1055/s-0044-1782618}
}
Kostenlos starten →